• wethepeopleofhk

HK government defies science and HK people's needs by supporting Sinovac vaccine

Updated: Mar 5, 2021

Unacceptably to Hong Kong (HK) people the HK government has now lowered its requirement for vaccine research records from Chinese drugmaker 'Sinovac Biotech' for experts’ assessment, citing an “urgency for vaccination.”

This sets a very dangerous precedent and is illegal under HK's international treaty obligations: this upends the whole basis of HK's Public Healthcare system based on Allopathic medicine.

Hong Kong (HK) government's COVID-19 vaccination program is being driven by politics not science! HK government has been delaying the rollout of its required international standard vaccination program by waiting for China's SinoVac 'CoronaVac' vaccine. This is a vaccine which has so far scientfically been proven inferior to international vaccines!

By comparison Singapore has been successfully vaccinating its citizens with American Pfizer vaccine since early January 2021!

This is a direct attack on the rule OF law and on HK people's human rights including our 'right to life', protection from torture and being subjected without her / his free consent to medical or scientific experimentation. (Please see Legal Issues below).

COVID-19 vaccination programs are the new worldwide protest space! Because of the history of CCP's China vaccines NO Chinese vaccine will be supported by HK people!

Strategy: To achieve 'herd immunity' HK government must now focus only on science and negotiating for HK people's support for a quality international standard vaccination program using the 'best' non-Chinese international vaccines (e.g. Pfizer, Moderna, etc.) Anything else will fail!

On 11 December 2020 Carrie Lam announced that HK has purchased 7.5 million doses of China developed and manufactured vaccine for COVID-19 Sinovac's 'CoronaVac': the first 1 million doses were supposed to be delivered to HK in January 2021, as of 7 February 2021 none have been delivered.

A complete picture needs to be understood about ALL China regulated COVID-19 vaccines. Key issues includes:

  • There are issues with Phase III clinial trials and peer reviews: regulatory approvals in China are at the core of the problems of corruption of all three China vaccine suppliers to HK;

  • China regulations are for age group only 18 - 59 years old (compared to international competitors using age group 16-85+): i.e. this vaccine is not suitable for age group 60+ years old which is needed for elderly care units, etc; nor does such a small age group ensure 'herd immunity' is achieved;

  • There are many 'health' exceptions under which people can not receive vaccination (i.e. more than international vaccines): this dramatically lowers the likelihood of achieving 'herd immunity'.

Legal issues

During a global pandemic our human rights are protected under international treaty UN W.H.O. 'International Health Regulations' (IHR) which governs HK legislation Cap.599 short titled "Prevention and Control of Disease Ordinance":

+ HK local legislation 'HK Bill of Rights Ordinance' (HKBORO) Article 2 'Right to Life' (ICCPR Article 6): "Every human being has the inherent right to life. This right shall be protected by law. No one shall be arbitrarily deprived of his life." The UN supreme human right is the 'right to life'.

+ HK local legislation 'HK Bill of Rights Ordinance' (HKBORO) Article 3 (ICCPR Article 7): "No one shall be subjected to torture or to cruel, inhuman or degrading treatment or punishment. In particular, no one shall be subjected without his free consent to medical or scientific experimentation." This article introduces another UN treaty obligation 'UN Convention against Torture and Other Cruel, Inhuman or Degrading Treatment or Punishment' (CAT).

+ Under ICESCR Article 12 (format added):

"1. The States Parties to the present Covenant recognize the right of everyone to the enjoyment of the highest attainable standard of physical and mental health.

2. The steps to be taken by the States Parties to the present Covenant to achieve the full realisation of this right shall include those necessary for:

(a) The provision for the reduction of the stillbirth-rate and of infant mortality and for the healthy development of the child;

(b) The improvement of all aspects of environmental and industrial hygiene;

(c) The prevention, treatment and control of epidemic, endemic, occupational and other diseases;

(d) The creation of conditions which would assure to all medical service and medical attention in the event of sickness."

CCP and HK government has to negotiate with HK people for political stability and reforms. This is HK people's health, the public purse belongs to HK people, and we have enough money for high quality non-China made vaccines! NO CHINESE VACCINES!

CCP please answer the following UN letters sent to you:

Our COVID-19 blogs includes:

Further references:

  1. RTHK 20 February 2021 'Get vaccinated early to help HK get over Covid'

  2. RTHK 19 February 2021 'Doctors, care home staff fear jabs will be mandatory'

  3. RTHK 18 February 2021 'HK to start inoculation drive on February 26'

  4. RTHK 18 February 2021 'Vaccinations can start as early as next week'

  5. RTHK 18 February 2021 'Cash incentive for Covid jab would not work: survey'

  6. RTHK 18 February 2021 'I'm going for the Sinovac jab: Carrie Lam'

  7. RTHK 18 February 2021 'People will become more accepting of jabs: expert'

  8. RTHK 18 February 2021 'Govt approves Sinovac jabs 'in the public interest''

  9. RTHK 17 February 2021 'Cowling: keep restrictions and aim for zero cases'

  10. RTHK 17 February 2021 'People harmed by Covid vaccines to get up to HK$3m'

  11. Apple Daily 17 February 2021 'Hong Kong medical team says ‘yes’ to Chinese-made vaccine without journal support'

  12. RTHK 17 February 2021 'Herd immunity harder to reach with Sinovac's use'

  13. RTHK 16 February 2021 'Experts recommend use of Sinovac Covid vaccine'

  14. RTHK 16 February 2021 'WHO gives green light to AstraZeneca Covid-19 jabs'

  15. Apple Daily 11 February 2021 'Hong Kong approves China-made vaccine despite gaps in data'

  16. RTHK 11 February 2021 'Govt advisers: frail elderly can get Biontech jab'

  17. RTHK 8 February 2021 'Govt locking down the wrong places: microbiologist'

  18. Apple Daily 8 February 2021 'Playing patriot games with the virus|Stephen Vines'

  19. Apple Daily 7 February 2021 'No border lockdown but your home will be locked down'

Hong Kong approves China-made vaccine despite gaps in data

Apple Daily 11 February 2021 (format added)

A group of Hong Kong government-appointed medical experts gave a China-made COVID-19 vaccine the green light despite still waiting on more data from its manufacturer, as the city looked to loosen social distancing restrictions after the Lunar New Year holiday.

The Advisory Panel on COVID-19 Vaccines unanimously deemed the safety and efficacy of Sinovac Biotech’s vaccines to be satisfactory. The panel made the decision during its Wednesday meeting but requested Sinovac still provide more data and information, including on post-injection antibodies and possible complications.

The government also indicated that some social distancing measures may be loosened from Feb. 18, including allowing restaurant dine-in services to run until 10 p.m. and for each table to have up to four people. Sports and entertainment facilities are also set to reopen if the pandemic is stabilized, according to the government. However, Hongkongers who want to use the facilities must register for the health code phone app.

The panel’s chairperson, Wallace Lau, said that data provided from the first and second clinical trials showed that Sinovac’s vaccine was suitable for people from different groups. Third-phase clinical data, which included findings from Brazil, Turkey and Indonesia, examined the vaccine’s efficacy and also side effects, and results were also found to be satisfactory, Lau said.

Lau said the panel was still waiting on data regarding the difference in efficacy between administering the vaccine shots 14 days apart and 28 days apart as well as the side effects and complications after the injections. The panel will reconvene in 14 days at the earliest, and discussion results will be handed to the government.

Sinovac’s data seemed to indicate that people who took their two shots 28 days apart had higher levels of antibodies compared to those who took their shots 14 days apart, according to panel member David Hui, adding that the panel has requested more related information.

The panel previously indicated that vaccine data and research must be published in a medical journal before it could be approved, but Hong Kong Chief Executive Carrie Lam said the COVID-19 vaccine should be exempted.

The panel has since made a U-turn on its original stance, with Lau saying that the panel has enough medical expertise to make informed decisions and that the public should trust its members’ judgement.

Lau said he believed the World Health Organization was assessing vaccines in a similar fashion and that there was no need for Sinovac’s vaccine to acquire WHO approval first.

Lam said that if any emergencies resulted from the vaccines, panel members should not be held personally responsible.

Click here for Chinese version.

No border lockdown but your home will be locked down

Apple Daily 7 February 2021 by Alex Lam Chi-yau

One year ago on Jan 24, the Hong Kong SARS Mutual Help Association, a group formed by SARS survivors, issued an open letter calling on the Hong Kong government to learn from the painful lessons of the SARS epidemic and do its utmost to prevent the epidemic. It also strongly urged the government to take all viable measures to reduce the impact of the Wuhan pneumonia on Hong Kong people, including banning non-locals who have visited Wuhan within the past month from entering Hong Kong and making it mandatory for all visitors or Hong Kong residents from the mainland to fill out health declaration forms. If the situation continued to deteriorate, the government must then consider denying entry to all visitors from the mainland until the epidemic in China shows improvement.

At about the same time, a trade union of public hospital staff launched an industrial action demanding that the government close the border immediately to prevent persons infected with the virus from entering the city, spreading the epidemic in the community and causing an outbreak. However, the government did not respond to these requests but instead is holding the health care workers involved in the industrial action liable for their actions.

One year later, the “closure” that the public saw was not imposed to deter the source of the virus from entering Hong Kong, but to stop residents from leaving the sealed off area where the virus was suspected to be spreading. The affected residents were unable to return to their homes or jobs. The irony is that the vast majority of the compulsory tests showed zero infections. With all that barking up the wrong tree, it is no wonder that Xi Jinping is worried.

Earlier, the Chief Executive said that the public does not have the right to choose among the three types of vaccines procured by the government. Later, she said we all misunderstood her and misjudged her.

Hong Kong Patients’ Voices conducted a survey earlier with patient groups on the vaccination arrangements announced by the government. The survey results showed that the respondents seemed to have a strong wait-and-see attitude towards vaccination. More than 40% of the respondents did not intend to receive the vaccine, did not care, or were undecided. A total of 16.7% of the respondents expected to get vaccinated within six months to one year.

Among the three vaccines procured by the Hong Kong government, the German-developed BioNTech doses by Fosun Pharmaceutical and the British-Swiss pharma giant AstraZeneca vaccines were more popular among respondents. Shanghai-based Fosun was the most preferred of the three options, with 33.8% of people choosing this vaccine as their first choice and 30.8% as their second choice. About 12.5% of people would not choose this vaccine.

While 28.6% of the respondents preferred the Cambridge-based Oxford-AstraZeneca vaccine, 32% of the respondents chose the vaccine as their second choice, and only 9.6% of respondents would not choose this vaccine.

Those choosing Beijing-based Sinovac Biotech’s vaccine as their first and second choices were relatively less. The percentage of people who would not opt for Sinovac’s vaccine was even higher than the other two vaccines combined.

The results of this survey are comparable to the findings of studies conducted by other organizations. The main reason is that the public is adopting a wait-and-see attitude towards vaccination. Combined with the fact that Sinovac’s vaccine still does not provide sufficient data for evaluation by experts, the winner of this vaccine battle is clearly in sight. However, it seems that the Hong Kong government is still not willing to give up on Sinovac. As to when the public will be able to receive the vaccine, it has been 'all talk but no action' with the official announcement of the vaccination program yet to be made. It turns out that the people of Hong Kong are not the only ones holding a wait-and-see attitude.

The year-long epidemic has caused the economy to slump, the unemployment rate to climb, and students to go to class only to stare at the screen of their computers or phones. The public is weary.

I can describe the [HK government] approach to the epidemic in 30 words.

Masks: Don’t wear them; if you do, they must be removed.

Vaccine: You don’t choose, the government chooses for you.

Lockdown: No border lockdown, but your home will be locked down.

I will not comment on whether the Hong Kong government has learned the lesson from SARS. No one has compared this epidemic with SARS, probably because the mortality rate is not as horrendous as that of SARS. The epidemic we are now facing is in fact an extended version of SARS. The difference is that in the face of SARS, the then Chief Executive Tung Chee-hwa was powerless in dealing with the epidemic, but fortunately, Hong Kong people united together, health care workers fought bravely against the disease, and SARS was ultimately defeated. In the face of the novel coronavirus, Hong Kong society is torn apart and health care workers are met with vicious treatment. Given the implementation of the National Security Law, I am not going to comment on the performance of Carrie Lam, but I do believe that the public can judge for themselves.

(Alex Lam Chi-yau is a patient advocate.)

Click here for Chinese version.

Another new crown vaccine has been conditionally approved by China

DW 6 February 2021 (Google translator)

Kexing's [Sinovac] new crown [coronavirus] vaccine [CoronaVac'] was approved for conditional listing, becoming the second domestically-made new crown vaccine approved for marketing in China after the inactivated vaccine of Sinopharm China Biotech. At the same time, Kexing announced the third phase of clinical research data.

(Deutsche Welle Chinese website) China's State Drug Administration website announced on Saturday (February 6) that on February 5, Beijing Kexing Zhongwei Biotechnology Co., Ltd. was conditionally approved for the inactivation of new coronaviruses. Vaccine (Vero cell) registration application. The vaccine is suitable for preventing the disease caused by the new coronavirus infection (COVID-19).

The Food and Drug Administration also pointed out that in accordance with the relevant provisions of the Vaccine Administration Law and the Drug Administration Law, emergency review and approval are carried out in accordance with the special drug approval procedures, and the marketing registration application is approved conditionally, and the vaccine marketing license holder is required to continue [to] carry out relevant research work, complete the conditional requirements, and submit follow-up research results in time.

This brief announcement did not mention the conditions attached to Kexing's vaccine approval. Kexing's new crown vaccine called "CoronaVac" became the second domestically produced new crown vaccine approved for marketing in China after the Sinopharm China Bio-New Crown Inactivated Vaccine.

How effective is the protection?

On the same day that Kexing's new crown vaccine was approved, Kexing announced on its website a preliminary statistical analysis of the third phase of the new crown clinical study data. The company said that as of December 16 last year, there were more than 12,000 medical staff aged 18 and over in Brazil who participated in the pilot study. The protective effect of two doses of vaccine 14 days apart was: The protective effect of all new coronary cases including the cases is 50.65%, the protective effect of new coronary cases with obvious symptoms and requiring medical treatment is 83.70%, and the protective effect of hospitalized, severe and dead cases is 100.00%.

According to the latest data released by Kexing, the Phase 3 clinical trial conducted in Turkey involved more than 900 high-risk medical staff aged 18 to 59 and more than 6,400 general persons at normal risk. As of December 23 last year, more than 1,300 people had completed two doses of vaccination. The results showed that 14 days after the two doses of vaccination, the protective effect of preventing the virus was 91.25%.

After obtaining the approval of the National Medical Products Administration of China, Kexing issued a statement stating that the conditional approval for listing this time is based on the two-month results of the overseas phase III clinical protection efficacy trial of Kerlaifu, and the final analysis has not yet been obtained. The data, effectiveness and safety results have yet to be further confirmed.

Attract developing countries

Although the overall effective rate of 50.65% of Kexing Vaccine has reached the minimum target of 50% set by the World Health Organization, its overall effective rate is far lower than that of Moderna and Pfizer/BioNTech's new crown vaccines. The overall effective rate of the latter two are 94% and 95% respectively. However, compared with the two new coronavirus vaccines developed by European and American companies, Kexing vaccine does not require ultra-low temperature preservation and is easier to transport and store in backward areas. Analysts believe this is also the reason why developing countries are attracted to purchase.

According to Kexing Company, in June 2020, 'CoronaVac' was first approved for emergency use in China, and since July, it has been carrying out emergency use for specific groups of people in China. Since January 2021, countries such as Indonesia, Turkey, Brazil, Chile, Colombia, Uruguay and Laos have successively approved the emergency use in the local area.

Hong Kong exempts Chinese-made vaccine from medical journal criterion

Apple Daily 7 February 2021

Hong Kong has lowered its requirement for vaccine research records that the city is asking from Chinese drugmaker Sinovac Biotech for experts’ assessment, citing an “urgency for vaccination.”

Sinovac Biotech now needs to provide phase 3 clinical data it has already given to the World Health Organization, because it has been unable to meet the Hong Kong government’s condition of supplying information published in medical journals, which would have lent more weight to the data.

The government’s COVID-19 advisers would assess the suitability of the Sinovac vaccine and make recommendations based on the same records presented to the WHO, according to a press release issued Friday night.

The Sinovac vaccines are supposed to be the first batch of jabs arriving in the city this month, under the government’s original plan. However, the producer has yet to publish any late-stage clinical data in journals.

In the press release, the government said it had requested Sinovac to provide the phase 3 clinical data passed to the WHO instead of published data, after the company said it had considerable difficulties compiling the records for publication in a short period of time.

The government acknowledged that the publication of research reports and data in medical journals indicated “the relevant research has undergone peer review and has a higher level of objectivity and acceptance.”

Sinovac had so far provided Hong Kong with phase 3 clinical data of trials conducted in Brazil that it had also submitted to other countries, the press release said. The drug company said it could submit as soon as this week the phase 3 data of trials conducted in Brazil and Turkey that it had handed to the WHO. Hong Kong’s Department of Health would then compile and pass the documents to the advisory panel next week for review.

Meanwhile, Hong Kong has also approved a German vaccine produced by BioNTech and its Chinese partner Fosun Pharma. The first batch of vaccines are expected to arrive by the end of February.

Sinovac said on Saturday that its COVID-19 vaccine had gained approval from China’s regulator for use by the public.

Click here for Chinese version

Apple Daily

24 views0 comments